AR-V7 in Castration Resistant Prostate Cancer
Dr. Emmanuel Antonarakis discusses treating chemo-naive metastatic hormone-sensitive prostate cancer and then discusses the impact of AR-V7 in CRPC.
Read More
Maryland
The Burden of Prostate Cancer Today and in the Future
In this presentation, Dr. Patrick Walsh expands upon Dr. Veda N. Giri’s introduction to the Philadelphia Prostate Cancer Consensus 2017. While she set forth the goals of the meeting and emphasized the importance of drafting centralized guidelines for genetic testing, Dr. Walsh focuses on PSA testing. He summarizes the past of PSA testing to give context to the urological community’s goals for the future.
Read More
Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?
Alan W. Partin, MD, Johns Hopkins Medical Institutions, Baltimore, Maryland, discusses which...
Read More
Ask the Expert: Which Non-Genomic Biomarkers Are the Most Useful for Stratifying Patients?
Alan W. Partin, MD, Johns Hopkins Medical Institutions, Baltimore, Maryland, discusses which...
Read More
Non-genomic Biomarkers for Early Diagnosis and Prognosis Prevention of Prostate Cancer
Dr. Alan W. Partin presented “Non-genomic Biomarkers for Early Diagnosis and Prognosis...
Read More